Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18911627 | 0.89 | HTR2A (0.42) | HTR2AHTR2CSIGMAR1NOTUMKMT2A | |
| SCHEMBL11237593 | 0.78 | KMT2A (0.44) | KMT2A | |
| SCHEMBL19608988 | 0.74 | EGFR (0.39) | HTR2AHTR2CKMT2A | |
| SCHEMBL19608952 | 0.73 | CYP19A1 (0.35) | HTR2AHTR2CHTR3A | |
| SCHEMBL31487049 | 0.72 | HTR2A (0.49) | HTR2AHTR2CSIGMAR1NOTUM | |
| SCHEMBL11236800 | 0.69 | KMT2A (0.53) | KMT2A | |
| SCHEMBL30703022 | 0.68 | HTR2A (0.64) | HTR2AHTR2CSIGMAR1NOTUM | |
| SCHEMBL761931 | 0.68 | HTR2A (0.64) | HTR2AHTR2CSIGMAR1NOTUM | |
| SCHEMBL11364424 | 0.67 | GLO1 (0.39) | KMT2A | |
| SCHEMBL29548539 | 0.67 | HTR2A (0.62) | HTR2AHTR2CSIGMAR1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6331631-B1 | Preparation of 1-butyl-4-piperidinylmethylamine | SMITHKLINE CORPORATION P.L.C. (GB) | 2001-12-18 | — | — | US | claimed |
| EP-0927163-A1 | PREPARATION OF 1-BUTYL-4-PIPERIDINYLMETHYLAMINE | SMITHKLINE BEECHAM PLC (GB) | 1999-07-07 | — | — | EP | claimed |
| WO-1998011067-A1 | PREPARATION OF 1-BUTYL-4-PIPERIDINYLMETHYLAMINE | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-03-19 | — | — | WO | claimed |
| WO-2017088746-A1 | NEW EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR AND APPLICATION THEREOF | 南京圣和药业股份有限公司 | 2017-06-01 | — | — | WO | disclosed |
| WO-2009097515-A2 | [A]-FUSED INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PIK3C2A | HTR2A 780/4885HTR2C 826/4885SIGMAR1 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.